Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-06-05 13:00:30

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

zacks.com - 2026-06-02 10:41:10

Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.

marketbeat.com - 2026-05-19 17:08:02

SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

globenewswire.com - 2026-05-12 08:30:00

Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 411,325 shares, a growth of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the shares of the stock

defenseworld.net - 2026-04-26 03:13:08

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients

globenewswire.com - 2026-04-17 16:01:00

Adagene is essentially a single-asset bet on ADG126, which is a masked anti-CTLA-4 antibody designed to improve tolerability in immuno-oncology. ADG126's upcoming AACR 2026 updates are likely the biggest near-term catalysts to look forward to this year. ADAG also has partnerships with Sanofi and Incyte that validate its pipeline to some extent. These also open the door to potential milestone and royalty payments.

seekingalpha.com - 2026-04-16 14:08:28